Clinical role of immunologic monitoring during OKT3 treatment.
Bhat
G
G
Department of Internal Medicine, University of Cincinnati Medical Center, Ohio, USA.
Schroeder
T J
TJ
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis / Q000097:blood; D000910:Antibodies, Heterophile / Q000096:biosynthesis / Q000097:blood; D000917:Antibody Formation; D001707:Biopsy, Needle; D004359:Drug Therapy, Combination; D005260:Female; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D015166:Monitoring, Immunologic; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D013997:Time Factors
D000888:Antibodies, Anti-Idiotypic; D000910:Antibodies, Heterophile; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3